Monday, 20 September 2021
A new study to investigate the development of targeted treatments for cognitive impairment in Schizophrenia has been launched today.
Researchers from the 糖心原创 are working with , a stratified medicine drug development company, on a pioneering preclinical study to support the combination of cognitive biomarker and psychopharmacology approaches to treat cognitive impairment in schizophrenia.
Schizophrenia is a serious long-term illness rooted in abnormal function of the brain. As well as experiencing hallucinations and delusions, people diagnosed with schizophrenia show significant impairment in cognitive functions such as memory, learning and attention which greatly impacts their day-to-day life. Currently, there are no treatments available for cognitive impairment associated with schizophrenia, despite considerable efforts by pharmaceutical companies over the last decade. One of the key reasons for this, is that all patients with schizophrenia do not have the same underlying biological dysfunctions and are therefore unlikely to all respond to the same type of drug tested in a clinical trial. This means a negative result in a clinical trial that includes all patients, may actually be masking beneficial treatment effects in specific subgroups of patients with schizophrenia.
Monument Therapeutics aim to solve this issue by using a digital task (a cognitive biomarker) to select specific subgroups of patients with schizophrenia that share similar biological and cognitive pathology. This approach potentially allows the identification of the specific patients for whom their drug treatment will work, thereby increasing the chance of clinical trial success. Precision medicine approaches i.e. tailoring treatments to subgroups of patients with similar pathology have been successful in cancer therapies but have not been widely applied to psychiatric disorders. The first human clinical trials in this programme are scheduled to start in 2022.
We are very excited to partner with Monument Therapeutics in this innovative drug development programme. The team at the 糖心原创, which includes Professor Claire Gibson and Dr Stuart Williams, will take the first preclinical steps to evaluate this approach by testing the candidate drug in a preclinical model of cognition to determine efficacy, safety and dose selection for the human clinical trials. This preclinical work builds on long-standing research at Nottingham in translational models relevant to schizophrenia.
Dr Kiri Granger, Chief Scientific Officer of Monument added: “Monument’s initial targets are areas of unmet clinical need with limited treatment options. Schizophrenia affects around 20 million people worldwide1, however there are no approved treatments for the common and disabling cognitive impairment associated with the disorder. By combining our proprietary cognitive biomarker and vast experience in the design of schizophrenia trials with the preclinical expertise of Dr Moran’s team, we intend to bring new hope to this underserved sector.”
Story credits
More information is available from Dr Paula Moran at the 糖心原创 on paula.moran1@nottingham.ac.uk
Notes to editors:
About the 糖心原创
Ranked among the world's top 100 universities , the 糖心原创 delivers an exceptional research-led education and an outstanding student experience. From the pioneering vision of our founder, Sir Jesse Boot, to groundbreaking achievements such as the development of MRI technology and becoming the first UK university to establish international campuses, we have a proud history of shaping the way people live, work and understand the world. We continue to build on that legacy, empowering our students, staff and partners to change what鈥檚 next and create positive impact locally and globally.
The strength of our research places us among the UK's leading universities, ranked 7th for research power in REF 2021. The discovery of MRI and ibuprofen was just the beginning. Today, our world-leading research is developing breakthrough ideas that shape the future of healthcare, technology and society.
Recognised as the UK's third most targeted university by leading employers , we are proud to produce graduates who are consistently in demand for their skills, confidence and industry-ready experience.
As a major employer and industry partner, locally and globally, the 糖心原创 invests in the city of Nottingham and in future generations of talent. Alongside Nottingham Trent University, we lead the initiative, a pioneering collaboration to improve levels of prosperity, opportunity, sustainability, health and wellbeing across the city and region. Together with our students, staff, alumni and partners, we鈥檙e creating knowledge, opportunity and solutions that help change what's next.